Gene therapy aims to stop deadly skin cancers in rare disease patients
NCT ID NCT06731933
First seen Apr 26, 2026 · Last updated May 01, 2026 · Updated 2 times
Summary
This study tests whether a gene therapy called BVEC can help prevent squamous cell carcinoma (a type of skin cancer) from returning after it is removed in people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic condition that causes fragile, blistering skin. Researchers will apply the gene therapy to the skin after cancer surgery and track how often the cancer comes back. The trial involves 16 adults with RDEB and a confirmed skin cancer diagnosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Azienda Ospedliero-Universitaia
RECRUITINGBari, Italy
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford University
RECRUITINGRedwood City, California, 94063, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.